Your Messages Inbox
Your Article Summary
See Latest ArticlesGenmab announces partial clinical hold on zalutumumab studies
Genmab, 06/04/09
Genmab A/S announced that the US Food and Drug Administration has placed a partial clinical hold on zalutumumab clinical studies being conducted under the US Investigational New Drug application, as well as requests for new studies. The affected studies are the Phase II study in patients with head and neck cancer considered incurable with standard treatment and the Phase I/II front line study of zalutumumab in combination with chemo-radiation.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
Retigabine Regulatory Update
GlaxoSmithKline, 11/03/09
Review calls for EHR action in Saskatchewan
Canadian Healthcare Technology, 11/20/09
New Drug Application Filed for Eldecalcitol, An Active Vitamin D3 Derivative
Chugai Pharmaceutical Co., 11/04/09
Article Search
Sponsor